newsfilter
← Earnings
Earnings Releases·

Retension Pharmaceuticals — Third Quarter 2026 Earnings Summary

Retension Pharmaceuticals completed an upsized initial public offering in October 2026, generating $51.75 million in gross proceeds to fund the development of its lead candidate, RTN-001, for uncontrolled and resistant hypertension. The company reported a net loss of $5.9 million for the third quarter of 2026, driven by increased research and development expenses related to its ongoing Phase 2b clinical trial. As of September 30, 2026, the company held $9.2 million in cash and cash equivalents, which would rise to approximately $54.3 million on a pro forma basis including the IPO proceeds. Topline data from the Phase 2b trial involving approximately 280 patients is expected in the first half of 2027.

Company
RETENSION PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology